Lilly Adds Centrexion’s Non-Opioid Pain Therapy to Pipeline

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 5 (Table of Contents)

Published: 31 May-2019

DOI: 10.3833/pdr.v2019.i5.2430     ISSN: 1756-7874

Section: Licensing



Eli Lilly has announced a license agreement to acquire the worldwide rights for CNTX-0290 from Centrexion Therapeutics, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details